All In Biotech

Drug Trial Radar · NCT01585025

Obeticholic Acid in Bile Acid Diarrhoea

Obeticholic Acid Treatment in Patients With Bile Acid Diarrhoea: an Open-label, Pilot Study of Mechanisms, Safety and Symptom Response.

Last checked: Nov 19, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Apr 2012

Primary completion

Jan 2014

Study completion Feb 2014

Sponsor

Lead sponsor
Imperial College Healthcare NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.

Conditions

  • Primary Bile Acid Malabsorption
  • Secondary Bile Acid Malabsorption
  • Chronic Diarrhoea

Interventions

  • Obeticholic acidDrug

    Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Fasting FGF19Time frame: Day 0, Day 15

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Hospital, Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.